Spondyloarthritis & psoriatic arthritis
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
Authors' conclusion
Patients treated with bimekizumab across the full axSpA disease spectrum, who achieved increasingly stringent clinical response criteria and lower disease activity at week 52, reported larger improvements in core axSpA domains.
Study context
- Population
- Patients with nr-axSpA and r-axSpA in BE MOBILE 1 and 2
- Comparison
- Patients achieving ASAS40 vs patients achieving ASAS20 but not ASAS40 at week 52
- Outcome
- Association of achievement of clinical response criteria and disease activity states (ASAS, ASDAS, BASDAI50) with change from baseline in PROs measuring core axial spondyloarthritis (axSpA) domains
- Follow-up
- Week 52
Methodological detailspooled regardless of treatment arm
- Pooled regardless of treatment arm
Pooled result
As reported in the abstract
Change from baseline in PROs, nr-axSpA
- Total spinal pain: ASAS40 vs ASAS20 not ASAS40
- −5.3 vs −2.8
- FACIT-Fatigue: ASAS40 vs ASAS20 not ASAS40
- 12.7 vs 6.7
- BASFI: ASAS40 vs ASAS20 not ASAS40
- −3.9 vs −1.8
- EQ-5D-3L: ASAS40 vs ASAS20 not ASAS40
- 0.30 vs 0.16
- WPAI-axSpA presenteeism: ASAS40 vs ASAS20 not ASAS40
- −35.4 vs −15.9
- Overall work impairment: ASAS40 vs ASAS20 not ASAS40
- −36.5 vs −12.9
- Activity impairment: ASAS40 vs ASAS20 not ASAS40
- −39.0 vs −21.0
- Sleep: ASAS40 vs ASAS20 not ASAS40
- 9.0 vs 3.9
Further pooled results
Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) · week 52
- Results similar for ASDAS and BASDAI50
nr-axSpA vs r-axSpA · week 52
- Similar amplitudes of improvement between nr-axSpA and r-axSpA
Original publication
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. Published 10 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →